Academic detailing improves identification and reporting of adverse drug events

Pharmacy World and Science

Volumn 21, Issue 3, 1999, Pages 110-115

  Schlienger, Raymond G ^a   Lüscher, Thomas F ^a,b   Schoenenberger, Ronald A ^a   Haefeli, Walter E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adverse drug event; Clinical pharmacist; Drug therapy; Hospital statistics; Latrogenic disease; Prospective study

Indexed keywords

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CLINICAL PHARMACY; CLINICAL RESEARCH; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HOSPITAL MANAGEMENT; HUMAN; HUMAN EXPERIMENT; PARAMEDICAL EDUCATION; PHARMACIST;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PHARMACISTS; PROSPECTIVE STUDIES;

EID: 0345517114     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008631926100     Document Type: Article

References (37)

1. Karch FE, Lasagna L. Adverse drug reactions. A critical review. JAMA 1975;234:1236-41.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998;279:1200-5.
3. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6.
4. Chatas CA, Vinson BE. Program for improvig adverse drug reaction reporting. Am J Hosp Pharm 1990;47:155-57.
5. Irvin LE, Grimmer SFM, Smith JC. Adverse drug reaction reporting. Br J Pharm Pract 1987;9:316-21.
6. Jacinto MS, Kleinman K. Hospital pharmacy program for reporting adverse drug reactions. Am J Hosp Pharm 1983;40:444-45.
7. Miwa LJ, Randall RJ. Adverse drug reaction program using pharmacist and nurse monitors. Hosp Pharm 1986;21:1140-46.
8. Winstanley PA, Irvin LE, Smith JC, Orme MLE, Breckenridge AM. Adverse drug reactions; A hospital pharmacy-based reporting scheme. Br J Clin Pharmacol 1989;28:113-16.
9. Bergman HD, Aoki VS, Black HJ, Leaverton PE, Dick RW, Wilson WR. A new role for the pharmacist in the detection and evaluation of adverse drug reactions. Am J Hosp Pharm 1971;28:343-50.
10. Keith MR, Bellanger-McCleery RA, Fuchs JE. Multidisciplinary program for detecting and evaluating adverse drug reactions. Am J Hosp Pharm 1989;46:1809-12.
11. Prosser TR, Kamysz PL. Multidisciplinary adverse drug reaction surveillance program. Am J Hosp Pharm 1990;47:1334-39.
12. Gardner P, Watson LJ. A pharmacist-based monitoring system. Clin Pharmacol Ther 1970;11:802-7.
13. Powell SH, Schwartz PA, Rayment CM, Marx CM. Pharmacy-based adverse drug reaction surveillance program. Am J Hosp Pharm 1982;39:1963-64.
14. Kilarski DJ, Ziegler B, Coarse J, Buchanan C. Adverse drug reaction reporting system: Developing a well-monitored program. Hosp Formul 1986;21:949-52.
15. Berry LL, Segal R, Sherrin TP, Fudge KA. Sensitivity and specificity of three methods of detecting adverse drug reactions. Am J Hosp Pharm 1988;45:1534-39.
16. Gilroy GW, Scollins MJ, Gay CG, Harry DJ, Giannuzzi DF. Pharmacy-coordinated program that encourages physician reporting of adverse drug reactions. Am J Hosp Pharm 1990;47:1327-33.
17. Kimelblatt BJ, Young SH, Heywood PM, Mandala AR, Gendelman S, Mehl B. Improved reporting of adverse drug reactions. Am J Hosp Pharm 1988;45:1086-89.
18. Koch KE. Use of standardized screening procedures to identify adverse drug reactions. Am J Hosp Pharm 1990;47:1314-20.
19. Bennett BS, Lipman AG. Comparative study of prospective surveillance and voluntary reporting in determining the incidence of adverse drug reactions. Am J Hosp Pharm 1977;34:931-36.
20. Schumock GT, Thornton JP, Witte KW. Comparison of pharmacy-based concurrent surveillance and medical record retrospective reporting of adverse drug reaction reporting. Am J Hosp Pharm 1991;48:1974-76.
21. McKenney JM, Wasserman AJ. Effect of advanced pharmaceutical services on the incidence of adverse drug reactions. Am J Hosp Pharm 1979;36:1691-97.
22. Hardman C, Lloyd B. Adverse drug reaction monitoring by ward pharmacists. J Clin Hosp Pharm 1982;7:71-73.
23. World Health Organization. International drug monitoring. Tech Rep Ser 1969;426:5-24.
24. Rawlins MD. Adverse reactions to drugs. Br Med J 1981;282:974-76.
25. deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997;278:1895-1906.
26. Gardner MJ, Altman DG. Statistics with confidence. London, England: British Medical Journal, 1989.
27. Bates DW, Spell N, Cullen J, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997;277:307-11.
28. Leape LL, Bates DW, Cullen DJ, et al. System analysis of adverse drug events. ADE Prevention Study Group. JAMA 1995;274:35-43.
29. Case RL, Guzzetti PJ. A survey of adverse drug reaction reporting programs in select hospitals. Hosp Pharm 1986;21:423-33.
30. Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospitalized patients. JAMA 1991;266:2847-51.
31. Schlienger RG, Lüscher TF, Haefeli WE. Clinical pharmacists' effect on drug information requests [letter]. Ann Pharmacother 1996;30:85.
32. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE prevention group. JAMA 1995;274:29-34.
33. Klein U, Gikalov I, Keller M, Hoigné R. "Drug-monitoring" in der Medizinischen Abteilung eines Regionalspitals. Schweiz Med Wschr 1972;102:1083-90.
34. Green DM. Pre-existing conditions, placebo reactions, and "side-effects". Ann Intern Med 1964;60:255-65.
35. Meyer FP, Tröger U, Röhl F-W. Adverse nondrug reactions: An update. Clin Pharmacol Ther 1996;60:347-52.
36. Johnson JM. Contributing to drug safety [editorial]. Am J Hosp Pharm 1990;47:1280.
37. Kennedy DL, Johnson JM, Nightingale SL. Monitoring of adverse drug events in hospitals. JAMA 1991;266:2878.